The study and its comparison
A 2013 trial randomized forty women with endometriosis-associated pain to melatonin or placebo for eight weeks. It reported reductions in pain and analgesic use alongside improved sleep. [1][2]
A 2023 trial randomized another forty women to a higher melatonin amount or placebo for two cycles or months. Thirty-four completed it. Average pain was 2.9 versus 3.3, a difference that was neither statistically nor clinically significant under the study criteria. [1][2]
What the finding establishes
A higher amount did not guarantee greater benefit. Differences in participants and protocols prevent treating these as a simple dose-response experiment. Complete funding was not established from the abstracts; the later study disclosed an author’s pharmaceutical employment and stock ownership. Neither trial establishes hormone normalization or a cure. [1][2]
A hypothetical distinction
Imagine a small positive trial is followed by a null trial. The uncertainty should appear in the article’s main conclusion.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- Efficacy of melatonin in the treatment of endometriosis: a phase II, randomized, double-blind, placebo-controlled trial.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product. - Adjuvant use of melatonin for pain management in endometriosis-associated pelvic pain-A randomized double-blinded, placebo-controlled trial.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.